Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Polycystic Ovary Syndrome 2Pituitary Neoplasms 2Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sezary Syndrome 1Sarcoma 1Prostatic Neoplasms 1Pituitary ACTH Hypersecretion 1Pancreatic Neoplasms 1Obesity 1Mycosis Fungoides 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Liposarcoma 1Diabetes Mellitus, Type 2 1Central Nervous System Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Docetaxel 171Radiotherapy 144Magnetic Resonance Spectroscopy 142Leuprolide 112Prednisone 108enzalutamide 102Radiosurgery 101Abiraterone Acetate 94Androgen Antagonists 91Goserelin 83bicalutamide 81gallium 68 PSMA-11 70Surveys and Questionnaires 63apalutamide 57Specimen Handling 56acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 55Radiation 47Gonadotropin-Releasing Hormone 45Standard of Care 44Biopsy 44Brachytherapy 42Radiotherapy, Intensity-Modulated 40Blood Specimen Collection 40darolutamide 39abiraterone 39cabazitaxel 35Exercise 35Carboplatin 33Pluvicto 32Triptorelin Pamoate 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Prostatic Neoplasms × Rosiglitazone × Clear all
NCT00182052 2013-05-23

Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer

Massachusetts General Hospital

Phase 3 Completed
100 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡